These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
143 related articles for article (PubMed ID: 38743241)
21. Pharmacokinetics of piperacillin/tazobactam in cancer patients with hematological malignancies and febrile neutropenia after chemotherapy. Álvarez JC; Cuervo SI; Garzón JR; Gómez JC; Díaz JA; Silva E; Sánchez R; Cortés JA BMC Pharmacol Toxicol; 2013 Nov; 14():59. PubMed ID: 24286231 [TBL] [Abstract][Full Text] [Related]
22. Addition of teicoplanin or vancomycin for the treatment of documented bacteremia due to gram-positive cocci in neutropenic patients with hematological malignancies: microbiological, clinical and economic evaluation. D'Antonio D; Staniscia T; Piccolomini R; Fioritoni G; Rotolo S; Parruti G; Di Bonaventura G; Manna A; Savini V; Fiorilli MP; Di Giovanni P; Francione A; Schioppa F; Romano F Chemotherapy; 2004 Jun; 50(2):81-7. PubMed ID: 15211082 [TBL] [Abstract][Full Text] [Related]
23. Teicoplanin versus vancomycin in the empirical treatment of febrile neutropenic patients. Chow AW; Jewesson PJ; Kureishi A; Phillips GL Eur J Haematol Suppl; 1993; 54():18-24. PubMed ID: 8365461 [TBL] [Abstract][Full Text] [Related]
25. Recommendations to achieve rapid therapeutic teicoplanin plasma concentrations in adult hospitalised patients treated for sepsis. Brink AJ; Richards GA; Cummins RR; Lambson J; Int J Antimicrob Agents; 2008 Nov; 32(5):455-8. PubMed ID: 18718742 [TBL] [Abstract][Full Text] [Related]
26. Population Pharmacokinetics of Teicoplanin and Its Dosing Recommendations for Neutropenic Patients With Augmented Renal Clearance for Hematological Malignancies. Sako KI; Nakamaru Y; Ikawa K; Maeda T; Goto S; Ishihara Y; Kato Y; Matsuda Y Ther Drug Monit; 2021 Aug; 43(4):519-526. PubMed ID: 34250964 [TBL] [Abstract][Full Text] [Related]
27. Measurement of Teicoplanin Concentration With Liquid Chromatography-Tandem Mass Spectrometry Method Demonstrates the Usefulness of Therapeutic Drug Monitoring in Hematologic Patient Populations. Chae H; Lee JJ; Cha K; Her SH; Kim HY; Han E; Kim M; Kim Y; Cho SY; Lee DG Ther Drug Monit; 2018 Jun; 40(3):330-336. PubMed ID: 29746433 [TBL] [Abstract][Full Text] [Related]
28. Population pharmacokinetics and pharmacodynamics of teicoplanin in neonates: making better use of C-reactive protein to deliver individualized therapy. Ramos-Martín V; Neely MN; McGowan P; Siner S; Padmore K; Peak M; Beresford MW; Turner MA; Paulus S; Hope WW J Antimicrob Chemother; 2016 Nov; 71(11):3168-3178. PubMed ID: 27543654 [TBL] [Abstract][Full Text] [Related]
29. Clinical practice guidelines for therapeutic drug monitoring of teicoplanin: a consensus review by the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring. Hanai Y; Takahashi Y; Niwa T; Mayumi T; Hamada Y; Kimura T; Matsumoto K; Fujii S; Takesue Y J Antimicrob Chemother; 2022 Mar; 77(4):869-879. PubMed ID: 35022752 [TBL] [Abstract][Full Text] [Related]
30. Evaluation of factors associated with the achievement of an optimal teicoplanin trough concentration . Takechi K; Yanagawa H; Zamami Y; Ishizawa K; Tanaka A; Araki H Int J Clin Pharmacol Ther; 2017 Aug; 55(8):672-677. PubMed ID: 28655381 [TBL] [Abstract][Full Text] [Related]
31. Daptomycin vs. glycopeptides in the treatment of febrile neutropenia: results of the Izmir matched cohort study. Sipahi OR; Kahraman H; Erdem HA; Yetkin F; Kaya S; Demirdal T; Tunccan OG; Karasahin O; Oruc E; Cag Y; Kurtaran B; Ulug M; Kutlu M; Avci M; Oztoprak N; Arda B; Pullukcu H; Tasbakan M; Yamazhan T; Kandemir O; Dizbay M; Sipahi H; Ulusoy S Infection; 2019 Apr; 47(2):259-266. PubMed ID: 30498901 [TBL] [Abstract][Full Text] [Related]
32. Prospective assessment of breakthrough infections and neurotoxicity and their association with cefepime trough concentrations in patients with febrile neutropenia. Gijsen M; Bekkers B; Maertens J; Lagrou K; Desmet S; Dreesen E; Peetermans WE; Debaveye Y; Spriet I Int J Antimicrob Agents; 2022 Jan; 59(1):106472. PubMed ID: 34757136 [TBL] [Abstract][Full Text] [Related]
33. Population pharmacokinetic study of teicoplanin in severely neutropenic patients. Lortholary O; Tod M; Rizzo N; Padoin C; Biard O; Casassus P; Guillevin L; Petitjean O Antimicrob Agents Chemother; 1996 May; 40(5):1242-7. PubMed ID: 8723474 [TBL] [Abstract][Full Text] [Related]
34. [Level of evidence for therapeutic drug monitoring of teicoplatin]. Boulamery A; Venisse N; Le Guellec C; Therapie; 2011; 66(1):45-50. PubMed ID: 21466777 [TBL] [Abstract][Full Text] [Related]
35. Factors on trough teicoplanin levels, associations between levels, efficacy and safety in patients with gram-positive infections. Wang T; Li N; Hu S; Xie J; Lei J; Wang Y; Zheng X; Xing J; Dong Y Int J Clin Pharmacol Ther; 2015 May; 53(5):356-62. PubMed ID: 25828639 [TBL] [Abstract][Full Text] [Related]
36. Significance of High Trough Concentration of Teicoplanin in the Treatment of Methicillin-Resistant Staphylococcus aureus Infection. Sato Y; Tokimatsu I; Suzuki Y; Itoh H; Hiramatsu K; Kadota J Chemotherapy; 2014; 60(4):274-8. PubMed ID: 25926288 [TBL] [Abstract][Full Text] [Related]
37. Outpatient treatment with intravenous antimicrobial therapy and oral levofloxacin in patients with febrile neutropenia and hematological malignancies. Bellesso M; Costa SF; Pracchia LF; Santos Dias LC; Chamone D; Dorlhiac-Llacer PE Ann Hematol; 2011 Apr; 90(4):455-62. PubMed ID: 20852999 [TBL] [Abstract][Full Text] [Related]
38. Recommended initial loading dose of teicoplanin, established by therapeutic drug monitoring, and outcome in terms of optimal trough level. Sato M; Chida K; Suda T; Muramatsu H; Suzuki Y; Hashimoto H; Gemma H; Nakamura H J Infect Chemother; 2006 Aug; 12(4):185-9. PubMed ID: 16944256 [TBL] [Abstract][Full Text] [Related]
39. Efficacy of extended infusion of β-lactam antibiotics for the treatment of febrile neutropenia in haematologic patients: protocol for a randomised, multicentre, open-label, superiority clinical trial (BEATLE). Laporte-Amargos J; Gudiol C; Arnan M; Puerta-Alcalde P; Carmona-Torre F; Huguet M; Albasanz-Puig A; Parody R; Garcia-Vidal C; Del Pozo JL; Batlle M; Tebé C; Rigo-Bonnin R; Muñoz C; Padullés A; Tubau F; Videla S; Sureda A; Carratalà J Trials; 2020 May; 21(1):412. PubMed ID: 32423462 [TBL] [Abstract][Full Text] [Related]
40. High-dose regimen to achieve novel target trough concentration in teicoplanin. Ueda T; Takesue Y; Nakajima K; Ichki K; Wada Y; Komatsu M; Tsuchida T; Takahashi Y; Ishihara M; Kimura T; Uchino M; Ikeuchi H J Infect Chemother; 2014 Jan; 20(1):43-7. PubMed ID: 24462424 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]